ReviewActa pharmaceutica Sinica. B2024

Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer.

Yifan Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.